Last reviewed · How we verify
NCT04648618
Obstructive Sleep Apnea and Diabetic Macular Edema Inflammatory Mediators
trial in Diabetic Macular Edema in 30 participants. Status unknown.
31 March 2020
Quick facts
| Lead sponsor | Uptown Eye Specialists |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 January 2018 |
| Primary completion | 31 March 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across Canada |
Conditions studied
- Diabetic Macular Edema — all drugs for Diabetic Macular Edema →
- Obstructive Sleep Apnea — all drugs for Obstructive Sleep Apnea →
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
Sponsor
Uptown Eye Specialists — full company profile →
Who can join
18 and older, any sex, with Diabetic Macular Edema or Obstructive Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Obstructive sleep apnea (OSA) is characterized by intermittent nocturnal hypoxemia, frequent arousals, fragmented sleep and daytime sleepiness. It has been shown to increase the risk of cardiac and vascular disease through multiple mechanisms including sympathetic hyperactivity, metabolic dysregulation, and activation of oxidative stress and inflammatory pathways. Diabetic retinopathy is a leading cause of blindness in the working age group, affecting 93 million people worldwide. Diabetic macular edema (DME) is a sight threatening complication and the most common cause of visual loss in patients with diabetes. OSA is frequently associated with diabetes with prevalence ranging from 23 to 86%. However, the relationship between OSA and DME is not well defined. The retina is especially susceptible to hypoxia, being one of the most metabolically active tissues. Many of the same inflammatory mediators have also been found to be elevated in patients with diabetic macular edema, including VEGF, VCAM-1 and IL-6. There has been no previous study examining the biochemical impact of OSA on patients with DME. We aim to explore this relationship by examining the differences in inflammatory markers expressed in patients with DME who have undergone an overnight sleep study, which is considered the gold standard diagnostic tool in OSA.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of obstructive sleep apnea on the expression of inflammatory mediators in diabetic macular edema.
Yang Y, Somani S. · · 2023 · cited 4× · PMID 35491659 · DOI 10.1177/11206721221099247
Verify or expand the search:
- PubMed search for NCT04648618
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Macular Edema
Currently open trials in the same condition.
- NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
- NCT06984822 — Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant · NA · recruiting
- NCT07038967 — Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification · recruiting
- NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
- NCT06549023 — Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy · NA · recruiting
Other Uptown Eye Specialists trials
Trials by the same sponsor.
- NCT05990712 — The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammator · Phase 4 · unknown
- NCT05766722 — Feasibility of an Artificial Intelligence Phone Call After Cataract Surgery · NA · unknown
- NCT05480839 — Manual Immediately Sequential Bilateral Cataract Surgery (M-ISBCS) vs Refractive Laser-Assisted Immediately Sequential B · NA · unknown
- NCT04856397 — Ozurdex in Suboptimal Diabetic Macular Edema Patients · NA · unknown
- NCT04856670 — Assessing Diabetes Mellitus on Cytokine Analysis and Macular Edema Following FLACS · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04648618 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uptown Eye Specialists
- Last refreshed: 1 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04648618.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing